After trial failure, will Amylyx pull ALS drug Relyvrio off the market?

[cafead]

via After reporting the failure of a confirmatory trial of its amyotrophic lateral sclerosis (ALS) drug Relyvrio (AMX0035), Amylyx Pharmaceuticals is uncertain whether it will pull the treatment from the market in the U.S. and in Canada, where it is known as Albrioza.

article source